CTXR
Price
$3.30
Change
+$0.04 (+1.23%)
Updated
Jan 17 closing price
Capitalization
27.95M
20 days until earnings call
PBYI
Price
$2.97
Change
-$0.05 (-1.66%)
Updated
Jan 17 closing price
Capitalization
145.79M
40 days until earnings call
Ad is loading...

CTXR vs PBYI

Header iconCTXR vs PBYI Comparison
Open Charts CTXR vs PBYIBanner chart's image
Citius Pharmaceuticals
Price$3.30
Change+$0.04 (+1.23%)
Volume$78.6K
Capitalization27.95M
Puma Biotechnology
Price$2.97
Change-$0.05 (-1.66%)
Volume$545.06K
Capitalization145.79M
CTXR vs PBYI Comparison Chart
Loading...
CTXR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PBYI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CTXR vs. PBYI commentary
Jan 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CTXR is a Hold and PBYI is a Hold.

Ad is loading...
COMPARISON
Comparison
Jan 18, 2025
Stock price -- (CTXR: $3.30 vs. PBYI: $2.97)
Brand notoriety: CTXR and PBYI are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CTXR: 21% vs. PBYI: 84%
Market capitalization -- CTXR: $27.95M vs. PBYI: $145.79M
CTXR [@Biotechnology] is valued at $27.95M. PBYI’s [@Biotechnology] market capitalization is $145.79M. The market cap for tickers in the [@Biotechnology] industry ranges from $368.92B to $0. The average market capitalization across the [@Biotechnology] industry is $2.37B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CTXR’s FA Score shows that 1 FA rating(s) are green whilePBYI’s FA Score has 1 green FA rating(s).

  • CTXR’s FA Score: 1 green, 4 red.
  • PBYI’s FA Score: 1 green, 4 red.
According to our system of comparison, PBYI is a better buy in the long-term than CTXR.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CTXR’s TA Score shows that 3 TA indicator(s) are bullish while PBYI’s TA Score has 5 bullish TA indicator(s).

  • CTXR’s TA Score: 3 bullish, 4 bearish.
  • PBYI’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, PBYI is a better buy in the short-term than CTXR.

Price Growth

CTXR (@Biotechnology) experienced а -9.09% price change this week, while PBYI (@Biotechnology) price change was -10.27% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.44%. For the same industry, the average monthly price growth was +2.66%, and the average quarterly price growth was -1.92%.

Reported Earning Dates

CTXR is expected to report earnings on Feb 07, 2025.

PBYI is expected to report earnings on Feb 27, 2025.

Industries' Descriptions

@Biotechnology (-1.44% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PBYI($146M) has a higher market cap than CTXR($28M). PBYI YTD gains are higher at: -2.623 vs. CTXR (-17.500). PBYI has higher annual earnings (EBITDA): 49.4M vs. CTXR (-40.86M). PBYI has more cash in the bank: 96.7M vs. CTXR (212). CTXR has less debt than PBYI: CTXR (320K) vs PBYI (86.4M). PBYI has higher revenues than CTXR: PBYI (244M) vs CTXR (0).
CTXRPBYICTXR / PBYI
Capitalization28M146M19%
EBITDA-40.86M49.4M-83%
Gain YTD-17.500-2.623667%
P/E RatioN/A6.32-
Revenue0244M-
Total Cash21296.7M0%
Total Debt320K86.4M0%
FUNDAMENTALS RATINGS
CTXR vs PBYI: Fundamental Ratings
CTXR
PBYI
OUTLOOK RATING
1..100
2574
VALUATION
overvalued / fair valued / undervalued
1..100
10
Undervalued
46
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9723
PRICE GROWTH RATING
1..100
6560
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CTXR's Valuation (10) in the Pharmaceuticals Major industry is somewhat better than the same rating for PBYI (46) in the Biotechnology industry. This means that CTXR’s stock grew somewhat faster than PBYI’s over the last 12 months.

CTXR's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as PBYI (100) in the Biotechnology industry. This means that CTXR’s stock grew similarly to PBYI’s over the last 12 months.

PBYI's SMR Rating (23) in the Biotechnology industry is significantly better than the same rating for CTXR (97) in the Pharmaceuticals Major industry. This means that PBYI’s stock grew significantly faster than CTXR’s over the last 12 months.

PBYI's Price Growth Rating (60) in the Biotechnology industry is in the same range as CTXR (65) in the Pharmaceuticals Major industry. This means that PBYI’s stock grew similarly to CTXR’s over the last 12 months.

PBYI's P/E Growth Rating (100) in the Biotechnology industry is in the same range as CTXR (100) in the Pharmaceuticals Major industry. This means that PBYI’s stock grew similarly to CTXR’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CTXRPBYI
RSI
ODDS (%)
Bullish Trend 11 days ago
90%
Bearish Trend 11 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 11 days ago
90%
Bearish Trend 11 days ago
88%
Momentum
ODDS (%)
Bullish Trend 11 days ago
81%
Bullish Trend 11 days ago
80%
MACD
ODDS (%)
N/A
Bullish Trend 11 days ago
83%
TrendWeek
ODDS (%)
Bearish Trend 11 days ago
86%
Bullish Trend 11 days ago
83%
TrendMonth
ODDS (%)
Bullish Trend 11 days ago
83%
Bullish Trend 11 days ago
83%
Advances
ODDS (%)
Bullish Trend 19 days ago
85%
Bullish Trend 12 days ago
84%
Declines
ODDS (%)
Bearish Trend about 1 month ago
86%
N/A
BollingerBands
ODDS (%)
Bearish Trend 11 days ago
86%
Bearish Trend 11 days ago
90%
Aroon
ODDS (%)
Bearish Trend 11 days ago
79%
N/A
View a ticker or compare two or three
Ad is loading...
CTXR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PBYI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GEMNX23.020.17
+0.74%
GMO Emerging Markets R6
MFWIX16.170.05
+0.31%
MFS Global Total Return I
CCASX79.950.19
+0.24%
Conestoga Small Cap Investors
GUBGX15.00N/A
N/A
Victory RS International A
HIAHX16.55-0.11
-0.66%
Hartford Healthcare HLS IA

CTXR and

Correlation & Price change

A.I.dvisor indicates that over the last year, CTXR has been loosely correlated with EYEN. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if CTXR jumps, then EYEN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CTXR
1D Price
Change %
CTXR100%
+1.23%
EYEN - CTXR
48%
Loosely correlated
-5.15%
TFFP - CTXR
37%
Loosely correlated
N/A
ALLO - CTXR
31%
Poorly correlated
-1.09%
ALEC - CTXR
31%
Poorly correlated
+1.79%
PBYI - CTXR
30%
Poorly correlated
-1.66%
More

PBYI and

Correlation & Price change

A.I.dvisor indicates that over the last year, PBYI has been loosely correlated with ABCL. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if PBYI jumps, then ABCL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PBYI
1D Price
Change %
PBYI100%
-1.66%
ABCL - PBYI
36%
Loosely correlated
+1.02%
ARVN - PBYI
35%
Loosely correlated
+2.67%
MDGL - PBYI
34%
Loosely correlated
+7.64%
VNDA - PBYI
33%
Loosely correlated
-1.80%
AURA - PBYI
31%
Poorly correlated
+1.30%
More